3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
10
Pulmonary Embolism
4
Venous Thrombosis
3
Neoplasms
3
Thrombosis
2
Multiple Myeloma
2
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Embolism
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Temozolomide
18
Magnetic Resonance Spectroscopy
15
Specimen Handling
13
Radiotherapy
13
Radiation
9
Biopsy
5
pembrolizumab
4
Radiotherapy, Intensity-Modulated
4
Nivolumab
4
Bevacizumab
4
vorasidenib
3
trametinib
3
Surgical Procedures, Operative
3
Spinal Puncture
3
tovorafenib
2
dabrafenib
2
Restraint, Physical
2
Leukapheresis
2
Ipilimumab
2
Genetic Therapy
2
Fluorodeoxyglucose F18
2
Eflornithine
2
Craniotomy
2
Carboplatin
2
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
2
vocimagene amiretrorepvec
1
veliparib
1
trastuzumab deruxtecan
1
tocilizumab
1
ribociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
apixaban
×
1 year
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled